Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Italian multicenter study, will enroll ~566 pts with oligometastatic hormone sensitive
prostate cancer who are candidates to receive treatment with apalutamide.
After 6 months from the start of treatment, patients will be randomized to receive local
treatment based on the investigator's choice ( either one between primary radiotherapy or
cytoreductive prostatectomy), in addition to apalutamide, or to continue just with medical
therapy.
Phase:
N/A
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators:
ASST Santi Paolo e Carlo European Institute of Oncology